Value Sense
NEW
Stock Screener with Intrinsic Value
TRY FOR FREE
×
PTGX

Protagonist Therapeutics, Inc. (PTGX)

Last Price$37.2(1.6%)
Market Cap$2,297.8M
LTM Free Cash Flow margin
70.8%
5Y avg
(366.2%)
Biotechnology industry median
(743.0%)
Stock quality & Intrinsic value
Sign up to view ->
Overvalued
Sign up to
learn more
-->
50+
undervalued stocks
Start beating the S&P 500

Protagonist Therapeutics, Inc. Free Cash Flow margin

Annual
Quarterly
LTM
Industry median
Company stand-alone
PTGX
Healthcare
Crunching data... Almost there!
Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Free Cash Flow margin
0.0%
0.0%
0.0%
16.0%
(163.1%)
(18,395.7%)
(254.8%)
(398.3%)
(409.8%)
(118.1%)
PTGX
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for PTGX and see if it's the right time to invest.
Dive in

Protagonist Therapeutics, Inc. (PTGX) Free Cash Flow margin comparison analysis

Crunching data... Almost there!

PTGX key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Crunching data... Almost there!

Discover more Stock Ideas

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Sign up to unlock

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Sign up to unlock

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
Sign up to unlock
More ideas -->
Loved by
investors
worldwide
10K+
Investors use our platform
#1
Top value investing hub with all necessary tools
1K+
Experienced investors in our community
4.9
Average rating across all rating platforms
Start for free ->

FAQ

1) What is Protagonist Therapeutics, Inc.'s Free Cash Flow margin?

As of today, Microsoft Corp's last 12-month Free Cash Flow margin is 70.8%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Free Cash Flow margin for Protagonist Therapeutics, Inc. have been (991.1%) over the past three years, and (384.5%) over the past five years.

2) Is Protagonist Therapeutics, Inc.'s Free Cash Flow margin Good?

As of today, Protagonist Therapeutics, Inc.'s Free Cash Flow margin is 70.8%, which is higher than industry median of (743.0%). It indicates that Protagonist Therapeutics, Inc.'s Free Cash Flow margin is Good.

3) How does Protagonist Therapeutics, Inc.'s Free Cash Flow margin compare to its peers?

As of today, Protagonist Therapeutics, Inc.'s Free Cash Flow margin is 70.8%, which is higher than peer median of 12.6%. The list of peers includes SMMT, UTHR, BNTX, NVO, REGN, ALNY, ARGX, VRTX, BGNE, MRNA.